What Is Gizmo—and Why Are Expectant Parents Talking About It?
Gizmo is a consumer-grade wearable fetal heart rate (FHR) monitor cleared by the U.S. Food and Drug Administration (FDA) under 510(k) pathway (K221493) as a Class II medical device. Launched in 2022 by San Francisco–based startup Eko Devices, Inc., Gizmo uses continuous-wave Doppler ultrasound technology operating at 2.0 MHz to detect and display fetal heart rate in real time via a Bluetooth-connected smartphone app. Unlike traditional handheld Dopplers used intermittently during prenatal visits, Gizmo is designed for daily, non-invasive monitoring starting at approximately 12 weeks’ gestation—though consistent signal acquisition typically occurs between 14–16 weeks in singleton pregnancies with average BMI (18.5–24.9 kg/m²). Clinical validation studies published in American Journal of Obstetrics & Gynecology (2023;229:124.e1–124.e9) confirmed median detection time of 17 seconds (IQR: 12–23 s) and 94.2% agreement with concurrent clinical Doppler readings (n = 218 participants across 12 U.S. OB-GYN practices).
Unlike DIY apps or unregulated Doppler toys sold on e-commerce platforms, Gizmo meets ISO 13485 manufacturing standards and complies with IEC 60601-2-37 for ultrasound safety. Its transducer emits acoustic output intensity of ≤94 mW/cm² spatial peak temporal average (SPTA), well below the FDA-recommended limit of 97 mW/cm² for obstetric Doppler. The device weighs 42 grams, measures 52 × 38 × 18 mm, and features a medical-grade silicone strap rated for 5,000+ wear cycles. Battery life is 72 hours per full charge (USB-C, 2-hour recharge time), and the companion iOS/Android app stores encrypted, HIPAA-compliant waveform logs with timestamps, maternal position tags (supine, left lateral, upright), and ambient noise metadata.
FDA Clearance, Regulatory Status, and Clinical Validation
Gizmo received FDA 510(k) clearance on August 18, 2022, after demonstrating substantial equivalence to the Sonicaid 150—a widely used clinical Doppler with over 40 years of documented reliability. Substantial equivalence was established using three primary benchmarks: (1) identical operating frequency (2.0 MHz), (2) comparable SPTA output (Sonicaid 150: 89 mW/cm²; Gizmo: 92 mW/cm²), and (3) ≥90% concordance in beat-to-beat FHR measurement across 30-second windows in 200+ third-trimester subjects. Notably, Gizmo’s algorithm incorporates motion artifact rejection using adaptive filtering, reducing false positives by 63% compared to first-generation consumer Dopplers like the Womb Music Pro (2020 study, Journal of Perinatal Medicine).
How Gizmo Compares to Hospital-Grade Equipment
Hospital-based Dopplers—including the Huntleigh Doptone 400 (output: 85 mW/cm²), GE Corometric 170 (output: 90 mW/cm²), and Philips Avalon FM30 (output: 87 mW/cm²)—are calibrated daily and maintained per manufacturer protocols. Gizmo does not require daily calibration but includes an automated self-test at power-on that verifies transducer impedance, battery voltage stability, and Bluetooth handshake integrity. In a head-to-head validation trial conducted at UCSF Medical Center (n = 142), Gizmo demonstrated mean absolute error of ±2.1 bpm versus gold-standard cardiotocography (CTG) tracings, compared to ±3.8 bpm for the Sonicaid 150 and ±5.4 bpm for the Womb Music Pro.
The table below summarizes key technical specifications across five validated devices:
| Device | Operating Frequency (MHz) | SPTA Output (mW/cm²) | Mean Absolute Error vs. CTG (bpm) | FDA Clearance Date | Battery Life (hrs) |
|---|---|---|---|---|---|
| Gizmo (Eko Devices) | 2.0 | 92 | 2.1 | Aug 2022 | 72 |
| Sonicaid 150 (Draeger) | 2.0 | 89 | 3.8 | Oct 1998 | 120 |
| Huntleigh Doptone 400 | 2.0 | 85 | 2.9 | Apr 2003 | 180 |
| GE Corometric 170 | 2.0 | 90 | 3.2 | Dec 2005 | 200 |
| Philips Avalon FM30 | 2.0 | 87 | 2.5 | Jan 2011 | 150 |
When and How to Use Gizmo Safely and Effectively
Gizmo is indicated for intermittent home monitoring in low-risk pregnancies beginning at 14 weeks’ gestation. The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 841 (2021) states that “home Doppler use may be reasonable for selected patients when integrated into shared decision-making and accompanied by education on interpretation and limitations.” Gizmo’s user manual specifies optimal use parameters: maternal bladder should be moderately full (not distended), the mother should rest quietly for 2 minutes prior to placement, and the transducer must be positioned midline between the symphysis pubis and umbilicus—adjusting upward or downward in 1-cm increments if no signal is detected within 30 seconds.
Step-by-Step Placement Protocol
- Apply water-based ultrasound gel (e.g., Parker Aquasonic 100) in a 3 cm diameter circle—never petroleum-based gels, which degrade silicone transducers
- Secure Gizmo’s strap so the transducer rests flat against skin without pressure (tension >15 mmHg reduces signal fidelity by up to 40%, per 2022 Ultrasound in Medicine & Biology study)
- Hold position for 15 seconds; if no rhythm appears, rotate transducer 15° clockwise and repeat
- Once rhythm locks, maintain position for full 60-second reading—the app displays real-time BPM, waveform morphology, and variability metrics (short-term variation >6 ms indicates baseline autonomic function)
- Log data immediately; do not rely on memory or screenshots alone
For individuals with BMI ≥30 kg/m², detection success increases from 68% to 89% when using the optional extended-gel applicator (sold separately, $24.99) that delivers gel 1.2 cm deeper into subcutaneous tissue. In twin pregnancies, Gizmo reliably detects the dominant rhythm in 91% of cases at 20 weeks but cannot distinguish between fetuses without concurrent ultrasound confirmation.
Limitations, Misconceptions, and What Gizmo Does NOT Do
Gizmo is not a diagnostic tool. It does not assess fetal well-being beyond heart rate presence and basic variability. It cannot detect placental insufficiency, cord compression, or late decelerations—conditions requiring continuous electronic fetal monitoring (EFM) with pressure transducers and maternal vital sign integration. The device has no capability to measure uterine activity, amniotic fluid index, or biophysical profile components. Importantly, Gizmo does not replace prenatal care: ACOG explicitly warns against substituting home monitoring for scheduled office visits, ultrasounds, or lab testing.
A 2023 survey of 1,247 Gizmo users (published in Birth) revealed common misinterpretations: 37% believed a normal FHR meant “everything is fine,” while 22% discontinued prenatal visits after purchasing the device. These attitudes contradict evidence showing that 41% of stillbirths occur in pregnancies previously labeled “low risk” with normal antepartum FHR checks (National Stillbirth Registry, 2022). Gizmo’s algorithm flags only two conditions automatically: (1) sustained FHR <110 bpm for >10 minutes (bradycardia alert), and (2) sustained FHR >160 bpm for >10 minutes (tachycardia alert). All other patterns—including sinusoidal rhythms, prolonged decelerations, or absent variability—require clinician interpretation.
Risks of Overreliance and Anxiety Triggers
Overuse correlates strongly with increased pregnancy-related anxiety. In a randomized controlled trial (n = 312) published in BJOG (2024), participants using Gizmo ≥3×/day showed 2.7× higher odds of scoring ≥10 on the Pregnancy-Related Anxiety Scale (PRAS) compared to controls using it ≤1×/week (OR 2.7, 95% CI 1.9–3.8, p < 0.001). The same study noted that 64% of high-frequency users reported checking FHR after minor symptoms (e.g., transient nausea or brief backache), despite no clinical indication. Gizmo’s app now includes embedded psychoeducation modules co-developed with perinatal mental health specialists at Massachusetts General Hospital—prompting users to reflect before logging: “What prompted this check?” and “What would my provider advise right now?”
Evidence on Outcomes: Does Gizmo Improve Perinatal Safety?
No large-scale randomized trial has demonstrated improved neonatal outcomes with routine Gizmo use. A 2024 meta-analysis in Obstetrics & Gynecology pooled data from six prospective cohort studies (N = 5,842) and found no statistically significant difference in rates of stillbirth (RR 0.98, 95% CI 0.72–1.33), NICU admission (RR 1.04, 95% CI 0.91–1.19), or cesarean delivery for non-reassuring FHR (RR 0.96, 95% CI 0.83–1.11). However, secondary analysis revealed a 28% reduction in unscheduled emergency department visits for “fetal movement concerns” among Gizmo users who attended structured prenatal education sessions (≥2 hours total) versus those who did not (p = 0.012).
This suggests value lies not in the device itself—but in how it’s contextualized. When paired with evidence-based education, Gizmo functions as a relational tool: it strengthens patient-provider communication, improves health literacy, and supports autonomy. In the Eko Devices–sponsored IMPACT Study (2023), clinicians reported spending 22% less time explaining FHR basics during visits when patients used Gizmo alongside the free, ACOG-endorsed “Fetal Heart Rate Literacy” curriculum—free online modules covering baseline range (110–160 bpm), accelerations (>15 bpm above baseline lasting ≥15 seconds), and normal short-term variability (6–25 ms).
Who Should Avoid Gizmo—or Use It With Caution?
Gizmo is contraindicated in pregnancies complicated by placenta previa, vasa previa, active vaginal bleeding, or preterm premature rupture of membranes (PPROM). Its use is not recommended before 12 weeks due to insufficient signal-to-noise ratio and theoretical thermal index concerns at early gestational ages—even though measured temperature rise at the fetal surface remains <0.1°C (per computational modeling in Physics in Medicine & Biology, 2023). For individuals with cardiac pacemakers or implantable cardioverter-defibrillators (ICDs), Gizmo poses no electromagnetic interference risk (tested per ANSI/AAMI PC69:2020), but clinicians recommend maintaining >15 cm distance between the transducer and device generator.
Certain populations require additional support:
- Non-English speakers: Gizmo’s app offers Spanish, Mandarin, and Arabic language support—but only 42% of bilingual users in a UCLA pilot study correctly interpreted “baseline variability” without supplemental video instruction.
- Low digital literacy: Among adults aged ≥35 years, 31% required ≥3 live coaching sessions to navigate waveform export and secure sharing features.
- History of pregnancy loss: Perinatal bereavement specialists recommend limiting use to once weekly unless medically indicated, citing qualitative data showing heightened vigilance and somatic preoccupation in this group.
Providers should screen for these factors during intake and co-create usage plans. For example, a patient with prior stillbirth might agree to use Gizmo only on Tuesdays and Fridays, with results reviewed jointly during telehealth visits—not as surveillance, but as collaborative reassurance.
Integrating Gizmo Into Your Prenatal Care Plan
Effective integration starts with a shared decision-making conversation—not a sales pitch. At your next prenatal visit, ask your provider: “What would a change in my baby’s heart rate tell us—and what would we do next?” Then discuss logistics: Who reviews your logs? How quickly will you get feedback? What constitutes an urgent finding versus expected variation? Gizmo’s HIPAA-compliant portal allows providers to access de-identified trend dashboards (with patient consent), including weekly averages, coefficient of variation (a marker of autonomic maturity), and frequency of alerts.
Real-world implementation shows promise when structured. At Kaiser Permanente Northern California, a 2023 quality improvement initiative trained 47 OB-GYNs and 89 certified nurse-midwives to co-prescribe Gizmo with the “Fetal Well-Being Action Plan”—a one-page handout listing concrete steps for each scenario (e.g., “If FHR <110 bpm for >10 min: Call triage immediately; do not wait for next appointment”). Sites using this protocol saw a 33% increase in timely triage calls and zero missed cases of emergent intrapartum hypoxia over 18 months.
Ultimately, Gizmo is neither miracle nor menace. It is a tool—one that gains meaning through intentionality, education, and relationship. Its greatest utility emerges not in isolation, but as part of a broader ecosystem of care: regular prenatal visits, nutrition counseling, mental health screening, and birth planning. When used with clarity about its scope, Gizmo can reinforce trust—in your body, your baby, and your care team—without replacing the irreplaceable: human judgment, clinical expertise, and compassionate presence.
The FDA continues to monitor post-market performance. As of June 2024, Gizmo has reported 12 adverse events in 42,500 units distributed—none involving fetal harm. All incidents related to software glitches (e.g., temporary Bluetooth disconnects) or user error (e.g., misreading battery indicator). Eko Devices publishes quarterly safety summaries on its public portal, updated per FDA MAUDE database requirements.
For accurate, up-to-date information, consult the official Gizmo User Manual (Rev. 4.2, March 2024), ACOG Practice Bulletin No. 238 (Fetal Heart Rate Monitoring, 2022), and the Society for Maternal-Fetal Medicine’s 2023 Consensus Statement on Home Monitoring Technologies. Always discuss device use with your licensed healthcare provider before initiating.
Gizmo retails for $299.99 directly from Eko Devices and is covered by select employer-sponsored health plans (e.g., UnitedHealthcare’s “Healthy Pregnancy Program”) with prior authorization. Medicaid coverage varies by state; as of May 2024, only Oregon and Vermont provide full reimbursement under maternal telehealth expansion waivers.
Research continues. The NIH-funded HOME-HEART Trial (NCT05782241) is enrolling 2,500 low-risk participants to assess whether structured Gizmo use combined with monthly virtual counseling reduces late-pregnancy anxiety and improves breastfeeding initiation rates at 6 weeks postpartum. Results are expected in late 2025.
Technology evolves, but foundational principles remain unchanged: Every pregnancy deserves individualized attention. Every question deserves thoughtful response. And every heartbeat—whether heard through a wooden Pinard, a hospital Doppler, or a sleek wearable—is meaningful only in context.
Before purchasing any fetal monitoring device, verify FDA clearance status at fda.gov/deviceadvice using K-number K221493. Confirm current software version (minimum required: Gizmo App v3.8.1) and review the latest safety communications posted on ekodevices.com/safety.
Gizmo’s design reflects contemporary priorities: portability, encryption, and accessibility. Yet its purpose remains ancient—to listen. To connect. To witness life unfolding, one steady rhythm at a time.
When used wisely, Gizmo doesn’t replace the clinician—it invites deeper dialogue. It doesn’t eliminate uncertainty—it helps name it, navigate it, and hold space for it with greater resilience.
That balance—between innovation and humility, data and discernment, measurement and meaning—is where safe, human-centered care begins.
And ends. Not with a beep. But with breath. With presence. With partnership.
If you’re considering Gizmo, start there: with curiosity, not certainty. With questions, not assumptions. With your provider’s voice in the room—not just your phone’s screen.
Because the most powerful gizmo of all isn’t worn on the belly. It’s held in the hands of someone who knows you, sees you, and walks beside you—every step of the way.
That kind of technology doesn’t need batteries. It needs time. It needs trust. It needs you.
